{"title":"Diagnostic value of serum microRNA21 and tumor markers CEA, CYFRA21-1 and NSE in early non-small cell lung cancer","authors":"S. Pan, Hui Wang, Yuanyuan Wang, Jia Wei, Na Liu","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.07.009","DOIUrl":null,"url":null,"abstract":"Objective To study the diagnostic value of serum microRNA21 and tumor markers CEA, CYFRA21-1 and NSE in early non-small cell lung cancer (NSCLC). Methods From January 2018 to March 2019, 22 patients with NSCLC in Daqing Longnan Hospital were selected as the study group, and 22 people who underwent health examination in our hospital during the same period were selected as the control group.The levels of serum microRNA21, major tumor markers and the relationship between pathological types and markers were observed and analyzed. Results The serum levels of miRNA-21 (2.15±0.9), CEA [(34.1±4.9)ng/mL], NSE [(27.1±2.2)ng/mL], and CYFRA21-1 [(12.1±1.2)ng/mL] in the study group were higher than those in the control group(t=6.524, 27.392, 23.339, 27.685, all P=0.000). The serum levels of miRNA-21 (1.88±1.14), CEA [(30.1±19.9)ng/mL], CYFRA21-1 [(12.8±5.2)ng/mL] in adenocarcinoma patients were lower than those in patients with squamous cell carcinoma, and the level of NSE [(26.1±3.2)ng/mL] was higher than that of patients with squamous cell carcinomas (t=1.158, 1.192, 0.423, 1.913, P=0.260, 0.247, 0.677, 0.070). The serum levels of miRNA-21 (2.58±0.96), CEA [(38.1±17.9)ng/mL], CYFRA21-1 [(16.8±6.2)ng/mL], NSE [(26.9±10.2)ng/mL] in NSCLC patients with Ⅲ~Ⅳ stage were higher than those in NSCLC patients with Ⅰ-Ⅱ stage, but only CYFRA21-1 had statistically significant difference(P<0.05), there were no statistically significant differences in the other three indicators (t=1.478, 0.574, 2.114, 1.015, P=0.155, 0.573, 0.047, 0.322). Conclusion The combined examination of serum microRNA-21 and tumor markers CEA, CYFRA21-1 and NSE in patients with NSCLC can effectively confirm the diagnosis, which is very important for the diagnosis, treatment and prognosis of patients.This diagnosis can be the first choice for patients with NSCLC. Key words: Carcinoma, non-small-cell lung; MicroRNA-21; Carcinoembryonic antigen; Cytokeratin 19-fragments; Neuron specific enolase; Early stage; Diagnostic value","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.07.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective To study the diagnostic value of serum microRNA21 and tumor markers CEA, CYFRA21-1 and NSE in early non-small cell lung cancer (NSCLC). Methods From January 2018 to March 2019, 22 patients with NSCLC in Daqing Longnan Hospital were selected as the study group, and 22 people who underwent health examination in our hospital during the same period were selected as the control group.The levels of serum microRNA21, major tumor markers and the relationship between pathological types and markers were observed and analyzed. Results The serum levels of miRNA-21 (2.15±0.9), CEA [(34.1±4.9)ng/mL], NSE [(27.1±2.2)ng/mL], and CYFRA21-1 [(12.1±1.2)ng/mL] in the study group were higher than those in the control group(t=6.524, 27.392, 23.339, 27.685, all P=0.000). The serum levels of miRNA-21 (1.88±1.14), CEA [(30.1±19.9)ng/mL], CYFRA21-1 [(12.8±5.2)ng/mL] in adenocarcinoma patients were lower than those in patients with squamous cell carcinoma, and the level of NSE [(26.1±3.2)ng/mL] was higher than that of patients with squamous cell carcinomas (t=1.158, 1.192, 0.423, 1.913, P=0.260, 0.247, 0.677, 0.070). The serum levels of miRNA-21 (2.58±0.96), CEA [(38.1±17.9)ng/mL], CYFRA21-1 [(16.8±6.2)ng/mL], NSE [(26.9±10.2)ng/mL] in NSCLC patients with Ⅲ~Ⅳ stage were higher than those in NSCLC patients with Ⅰ-Ⅱ stage, but only CYFRA21-1 had statistically significant difference(P<0.05), there were no statistically significant differences in the other three indicators (t=1.478, 0.574, 2.114, 1.015, P=0.155, 0.573, 0.047, 0.322). Conclusion The combined examination of serum microRNA-21 and tumor markers CEA, CYFRA21-1 and NSE in patients with NSCLC can effectively confirm the diagnosis, which is very important for the diagnosis, treatment and prognosis of patients.This diagnosis can be the first choice for patients with NSCLC. Key words: Carcinoma, non-small-cell lung; MicroRNA-21; Carcinoembryonic antigen; Cytokeratin 19-fragments; Neuron specific enolase; Early stage; Diagnostic value
期刊介绍：
Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
